9.135
前日終値:
$8.88
開ける:
$8.97
24時間の取引高:
12,681
Relative Volume:
0.01
時価総額:
$1.23B
収益:
$175.51M
当期純損益:
$-78.02M
株価収益率:
-17.24
EPS:
-0.53
ネットキャッシュフロー:
$-34.18M
1週間 パフォーマンス:
+3.22%
1か月 パフォーマンス:
+16.67%
6か月 パフォーマンス:
+13.76%
1年 パフォーマンス:
+67.61%
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
名前
Aurinia Pharmaceuticals Inc
セクター
電話
250-744-2487
住所
#140, 14315 - 118 AVENUE, EDMONTON, BC
AUPH を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
AUPH
Aurinia Pharmaceuticals Inc
|
9.135 | 1.21B | 175.51M | -78.02M | -34.18M | -0.53 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.27 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.31 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
327.53 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
569.10 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.27 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2022-11-04 | ダウングレード | Oppenheimer | Outperform → Perform |
2022-05-05 | 再開されました | Cantor Fitzgerald | Overweight |
2021-12-10 | アップグレード | Oppenheimer | Perform → Outperform |
2021-10-28 | ダウングレード | Oppenheimer | Outperform → Perform |
2021-01-25 | 繰り返されました | H.C. Wainwright | Buy |
2020-11-03 | 繰り返されました | H.C. Wainwright | Buy |
2020-06-17 | 開始されました | BTIG Research | Buy |
2020-05-05 | 開始されました | Cowen | Outperform |
2020-01-10 | 開始されました | Jefferies | Buy |
2019-12-16 | 繰り返されました | H.C. Wainwright | Buy |
2018-03-16 | 繰り返されました | Cantor Fitzgerald | Overweight |
2018-02-08 | 開始されました | RBC Capital Mkts | Outperform |
2017-10-30 | 繰り返されました | H.C. Wainwright | Buy |
2017-05-18 | 繰り返されました | H.C. Wainwright | Buy |
2017-04-11 | 開始されました | Cantor Fitzgerald | Overweight |
2017-03-22 | 繰り返されました | FBR & Co. | Outperform |
2016-12-30 | 繰り返されました | H.C. Wainwright | Buy |
2016-08-17 | 繰り返されました | H.C. Wainwright | Buy |
2016-06-30 | 開始されました | H.C. Wainwright | Buy |
2015-05-08 | 開始されました | MLV & Co | Buy |
すべてを表示
Aurinia Pharmaceuticals Inc (AUPH) 最新ニュース
What analysts say about Aurinia Pharmaceuticals Inc. stockFast-track wealth growth - Autocar Professional
What drives Aurinia Pharmaceuticals Inc. stock priceHigh-yield investments - jammulinksnews.com
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025 - BioSpace
Aurinia Pharmaceuticals to Announce Q2 2025 Financial Results - TipRanks
Aurinia Pharmaceuticals: LUPKYNIS Growth and AUR200 Pipeline Fuel Long-Term Value - AInvest
ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting - Yahoo.co
Aurinia Pharmaceuticals Inc. Stock Analysis and ForecastBreakthrough investment results - jammulinksnews.com
Is Aurinia Pharmaceuticals Inc. a good long term investmentFree AI-Backed Trading Signals - Autocar Professional
(AUPH) Technical Data - news.stocktradersdaily.com
Aurinia Pharmaceuticals (NASDAQ:AUPH) Delivers Shareholders Favorable 52% Return Over 1 Year, Surging 5.5% in the Last Week Alone - 富途牛牛
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Yahoo
What makes Aurinia Pharmaceuticals Inc. stock price move sharplyDaily Breakout Picks - Newser
How Aurinia Pharmaceuticals Inc. stock performs during market volatilityFree Stock Investment Discussion Area - Newser
Why Aurinia Pharmaceuticals Inc. stock attracts strong analyst attentionReal Trader Insights - Newser
How did AUPH's Q3 2024 earnings surprise impact short-term traders? - AInvest
Trading (AUPH) With Integrated Risk Controls - news.stocktradersdaily.com
Wheat from chaff in BAFF: APRIL’s advent for Aurinia? - BioWorld MedTech
The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity (NASDAQ:AUPH) - Seeking Alpha
Retail Bulls Charge Into Aurinia Pharmaceuticals Ahead Of Autoimmune Trial Results - MSN
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options - Nasdaq
Implied Volatility Surging For Aurinia Pharmaceuticals Stock Options - Barchart.com
Leerink Partners Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH) - The Globe and Mail
Aurinia’s aritinercept shows promising results in phase 1 study - Investing.com
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) - New Castle News
Aurinia Pharmaceuticals Inc.(NasdaqGM: AUPH) added to Russell 2000 Defensive Index - MarketScreener
(AUPH) Trading Report - news.stocktradersdaily.com
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025 - The Joplin Globe
Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains? - Yahoo Finance
Aurinia shares rise ahead of key autoimmune therapy data - Proactive financial news
Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) have lost 50%, as stock drops 5.0% this past week - simplywall.st
With 51% institutional ownership, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a favorite amongst the big guns - Yahoo Finance
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA
California State Teachers Retirement System Sells 13,824 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by Bank of America Corp DE - Defense World
Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock? - MSN
As Edmonton biotech industry booms, Launa Aspeslet steps up to guide further success - Taproot Edmonton
Wellington Management Group LLP Buys New Shares in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Aurinia Pharmaceuticals Inc (AUPH) 財務データ
収益
当期純利益
現金流量
EPS
Aurinia Pharmaceuticals Inc (AUPH) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Greenleaf Peter | Chief Executive Officer |
Mar 03 '25 |
Sale |
8.00 |
195,593 |
1,564,744 |
1,953,892 |
Greenleaf Peter | Chief Executive Officer |
Mar 04 '25 |
Sale |
7.92 |
164,947 |
1,306,380 |
1,788,945 |
Keenan Greg | Chief Medical Officer |
Mar 03 '25 |
Sale |
8.00 |
12,239 |
97,912 |
161,789 |
Miller Joseph M | Chief Financial Officer |
Mar 03 '25 |
Sale |
8.00 |
61,859 |
494,872 |
633,515 |
Miller Joseph M | Chief Financial Officer |
Mar 04 '25 |
Sale |
7.92 |
56,154 |
444,740 |
577,361 |
Robertson Stephen P. | EVP, General Counsel |
Mar 03 '25 |
Sale |
8.00 |
64,872 |
518,976 |
566,883 |
Robertson Stephen P. | EVP, General Counsel |
Mar 04 '25 |
Sale |
7.92 |
57,607 |
456,247 |
509,276 |
Donley Matthew Maxwell | Chief Operating Officer |
Mar 03 '25 |
Sale |
8.00 |
65,902 |
527,216 |
739,456 |
Donley Matthew Maxwell | Chief Operating Officer |
Mar 04 '25 |
Sale |
7.92 |
58,991 |
467,209 |
680,465 |
TANG KEVIN | Director |
Mar 04 '25 |
Buy |
7.96 |
748,038 |
5,953,304 |
10,029,500 |
大文字化:
|
ボリューム (24 時間):